Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 121 to 135 of 984 results for death

  1. Balloon dilatation of systemic to pulmonary arterial shunts in children (HTG48)

    Evidence-based recommendations on balloon dilatation of systemic to pulmonary arterial shunts in children. This involves inflating a balloon inserted into the area so blood can flow through more easily.

    HealthTech guidance
    Published
    28 July 2004
    View recommendations

    Sections for HTG48

  2. Extracorporeal membrane oxygenation for severe acute respiratory failure in adults (HTG260)

    Evidence-based recommendations on extracorporeal membrane oxygenation for severe acute respiratory failure in adults. This involves using a tube to carry blood from the right side of the heart and then pump it through an artificial lung where it picks up oxygen.

    HealthTech guidance
    Published
    27 April 2011
    View recommendations

    Sections for HTG260

  3. Irreversible electroporation for treating pancreatic cancer (HTG437)

    Evidence-based recommendations on irreversible electroporation for treating pancreatic cancer. This involves inserting special needles into the tumour in the pancreas and using short electrical pulses to destroy the cancer cells.

    HealthTech guidance
    Published
    3 May 2017
    View recommendations

    Sections for HTG437

  4. Percutaneous radiofrequency ablation for primary or secondary lung cancers (HTG244)

    Evidence-based recommendations on percutaneous radiofrequency ablation for primary or secondary lung cancers. This involves inserting 1 or more electrodes (needle-like probes) through the chest into the lung and using an electrical current to produce heat to destroy the cancer cells.

    HealthTech guidance
    Published
    15 December 2010
    View recommendations

    Sections for HTG244

  5. Remdesivir and tixagevimab plus cilgavimab for treating COVID-19 (TA971)

    Evidence-based recommendations on remdesivir (Veklury) and tixagevimab plus cilgavimab (Evusheld) for treating COVID-19.

    Technology appraisal guidance
    Published
    8 May 2024
    View recommendations

    Sections for TA971

  6. Coil embolisation of ruptured intracranial aneurysms (HTG64)

    Evidence-based recommendations on coil embolisation of ruptured intracranial aneurysms. This involves passing a thin tube through the body to place coils inside the aneurysm.

    HealthTech guidance
    Published
    26 January 2005
    View recommendations

    Sections for HTG64

  7. Balloon dilatation of pulmonary valve stenosis (HTG40)

    Evidence-based recommendations on balloon dilatation of pulmonary valve stenosis. This involves passing a small deflated balloon up through a blood vessel at the top of the leg and into the blocked area in the heart.

    HealthTech guidance
    Published
    23 June 2004
    View recommendations

    Sections for HTG40

  8. Ruxolitinib for treating acute graft versus host disease that responds inadequately to corticosteroids in people 12 years and over (TA1054)

    Evidence-based recommendations on ruxolitinib (Jakavi) for treating acute graft versus host disease that has an inadequate response to corticosteroids in people 12 years and over.

    Technology appraisal guidance
    Published
    15 April 2025

    Sections for TA1054

  9. Ex-situ machine perfusion devices for lung transplants

    In development Reference number: GID-HTE10084 Expected publication date:  21 October 2026

    Health technology evaluations
    In development

  10. Brodalumab for treating moderate to severe plaque psoriasis (TA511)

    Evidence-based recommendations on brodalumab (Kyntheum) for treating moderate to severe plaque psoriasis in adults.

    Technology appraisal guidance
    Published
    21 March 2018
    View recommendations

    Sections for TA511

  11. Vemurafenib for treating locally advanced or metastatic BRAF V600 mutation‑positive malignant melanoma (TA269)

    Evidence-based recommendations on vemurafenib (Zelboraf) for treating advanced BRAF V600-positive malignant melanoma in adults.

    Technology appraisal guidance
    Last updated
    1 January 2015
    View recommendations

    Sections for TA269

  12. Rivaroxaban for preventing adverse outcomes after acute management of acute coronary syndrome (TA335)

    Evidence-based recommendations on rivaroxaban (Xarelto) for preventing atherothrombotic events, such as heart attack and stroke, after acute coronary syndrome in adults.

    Technology appraisal guidance
    Published
    25 March 2015
    View recommendations

    Sections for TA335

  13. Endoscopic submucosal dissection knives for the resection of complex colorectal polyps with suspected submucosal invasion

    In development Reference number: GID-HTE10072 Expected publication date:  19 November 2026

    Health technology evaluations
    In development

  14. Postnatal care (QS37)

    This quality standard covers routine postnatal care in the first 8 weeks after birth. It describes high-quality care in priority areas for improvement.

    Quality standard
    Last updated
    27 September 2022
    View quality statements

    Sections for QS37

  15. Non-surgical reduction of the myocardial septum (HTG18)

    Evidence-based recommendations on non-surgical reduction of myocardial septum. This involves inserting a catheter into the femoral artery and passing it up into the heart under X-ray control.

    HealthTech guidance
    Published
    25 February 2004
    View recommendations

    Sections for HTG18